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Abstract
Background: Molecular markers identifying alterations in proliferation and apoptotic pathways could be
particularly important in characterizing high-risk normal or pre-neoplastic tissue. We evaluated the
following markers: Ki67, Minichromosome Maintenance Protein-2 (Mcm-2), activated caspase-3 (a-casp3)
and Bcl-2 to determine if they showed differential expression across progressive degrees of intraepithelial
neoplasia and cancer in the prostate. To identify field effects, we also evaluated whether high-risk
expression patterns in normal tissue were more common in prostates containing cancer compared to
those without cancer (supernormal), and in histologically normal glands adjacent to a cancer focus as
opposed to equivalent glands that were more distant.
Methods:  The aforementioned markers were studied in 13 radical prostatectomy (RP) and 6
cystoprostatectomy (CP) specimens. Tissue compartments representing normal, low grade prostatic
intraepithelial neoplasia (LGPIN), high grade prostatic intraepithelial neoplasia (HGPIN), as well as different
grades of cancer were mapped on H&E slides and adjacent sections were analyzed using
immunohistochemistry. Normal glands within 1 mm distance of a tumor focus and glands beyond 5 mm
were considered "near" and "far", respectively. Randomly selected nuclei and 40 × fields were scored by
a single observer; basal and luminal epithelial layers were scored separately.
Results: Both Ki-67 and Mcm-2 showed an upward trend from normal tissue through HGPIN and cancer
with a shift in proliferation from basal to luminal compartment. Activated caspase-3 showed a significant
decrease in HGPIN and cancer compartments. Supernormal glands had significantly lower proliferation
indices and higher a-casp3 expression compared to normal glands. "Near" normal glands had higher Mcm-
2 indices compared to "far" glands; however, they also had higher a-casp3 expression. Bcl-2, which varied
minimally in normal tissue, did not show any trend across compartments or evidence for field effects.
Conclusion:  These results demonstrate that proliferation and apoptosis are altered not only in
preneoplastic lesions but also in apparently normal looking epithelium associated with cancer. Luminal cell
expression of Mcm-2 appears to be particularly promising as a marker of high-risk normal epithelium. The
role of apoptotic markers such as activated caspase-3 is more complex, and might depend on the
proliferation status of the tissue in question.
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Background
Disturbances of proliferation and apoptosis are funda-
mental events in early carcinogenesis, and may be useful
in characterizing tissue that is histologically normal but at
high-risk for neoplastic growth. Field effect – referring to
genetically altered but phenotypically normal-looking
cells in the vicinity of a cancer focus [1-3] – has been stud-
ied fairly extensively in sites such as the oral cavity and
lung.[4,5] Field effects have not been well characterized as
yet in the prostate, although identification of these events
could play an especially profound role in chemopreven-
tion research and clinical practice. Due to the validity lim-
itations of PSA testing and the lack of imaging tools which
make blind biopsies necessary, benign prostatic tissue is
sampled very commonly. In the U.S., approximately 1.5
million prostate biopsies are performed annually, and the
great majority are negative for cancer.[6] All biopsies are
likely to contain normal-appearing epithelium that could
potentially harbor changes characteristic of high-risk
changes at the genetic, protein, cytomorphological level.
Therefore, biomarkers identifying high-risk non-cancer
tissue could be very useful as intermediate endpoints in
chemoprevention studies, and as tools for classifying
patients with negative biopsies according to their need for
close follow-up.
In this study, we analyzed the expression of the prolifera-
tion markers Ki67 and Mcm-2, the apoptotic marker a-
casp3 and the anti-apoptotic marker Bcl-2. First, we eval-
uated whether these markers showed differential expres-
sion across progressive degrees of intraepithelial
neoplasia and cancer. Because proliferation occurs pre-
dominantly in the basal layer, and apoptosis in the lumi-
nal layer of the normal prostatic epithelium, we
determined whether early dysplastic progression was
associated with a detectable shift towards proliferation
and suppressed apoptosis in the luminal compartment. In
order to address field effects in prostatic carcinogenesis,
we first determined whether normal tissue from prostates
that harbored a focus of cancer had different proliferative
and apoptotic characteristics than normal tissue from
prostates that did not contain cancer (designated as
"supernormal"). Finally, we analyzed normal and HGPIN
glands adjoining a focus of cancer to determine if cells
within these epithelial structures showed high-risk expres-
sion patterns when compared to similar cells that are dis-
tant from a cancer focus.
Methods
Subjects and specimens
Thirteen RP specimens containing prostate cancer and six
CP samples not containing prostate cancer were retrieved
from Northwestern Memorial Hospital's pathology repos-
itory after appropriate Institutional Review Board
approval. The radical prostatectomy specimens were pro-
cured from prostate cancer cases with Gleason scores rang-
ing from five to nine. The most representative block(s)
containing compartments of normal, LGPIN, HGPIN, and
cancer were selected for further analysis. Although a diag-
nosis of LGPIN is not used in clinical reports, established
criteria for identifying acinar structures with LGPIN can be
used in research studies. LGPIN lesions were defined
based on the following nuclear features: variation in
nuclear size, nucleomegaly, normal or slightly increased
chromatin content, and small or inconspicuous nucle-
oli.[7,8] HGPIN lesions had large nuclei with very promi-
nent nucleoli. Both LGPIN and HGPIN lesions had either
an intact or an attenuated basal cell layer. Cancerous areas
were further subcategorized into three compartments:
low-grade cancer (LGCA), intermediate grade cancer
(IGCA) and high grade cancer (HGCA) based on Gleason
grades 1–2, 3 and 4–5 respectively. Tissue representing all
six compartments was mapped out on hematoxylin and
eosin (H&E) stained slides using marker pens. In addi-
tion, normal areas were mapped for six cystoprostatec-
tomy specimens obtained from patients undergoing
treatment for bladder cancer. Prostates from cystoprosta-
tectomy specimens were examined grossly for suspicious
areas, which if present, were submitted for histopatho-
logic examination. Otherwise, a minimum of four ran-
dom sections were taken. All sections were studied in
detail by a pathologist (MRP) to rule out the presence of
cancer in the prostate.
Immunohistochemistry
Five unstained sections were cut from each sample. The
first section was stained by H&E and subsequent sections
were immunostained for Ki67 (Dako, 1:200), Mcm-2
(Novocastra, 1:40), a-casp3 (Cell Signaling, 1:400), and
Bcl-2 (Dako, 1:200) using a Dako autostainer. For all the
antibodies, antigen retrieval was carried out in a steamer
using Target Retrieval Solution (S1699, Dako, Carpinte-
ria, CA). After treating with the appropriate antibody, sec-
tions were incubated with a ready-to-use anti-mouse
secondary antibody from Dako (EnVision Plus®) and
color reaction was developed using diaminobenzidine
(DAB) as the chromagen. The slides were then counter-
stained with hematoxylin. Suitable positive and negative
controls were run in tandem.
Scoring and statistical analysis
Progressive compartments comparison
Areas corresponding to the marked regions on the H&E
slides were mapped onto the immunostained slides. Ki67
and Mcm-2 immunostained slides were mounted with
photo-etched cover slips (Bellco Glass Inc.). These cover
slips have 520 alphanumeric squares (grids) etched on
them, each measuring 0.6 × 0.6 mm. At the outset, the
grid locations for supernormal, normal, LGPIN, HGPIN,
LGCA, IGCA, and HGCA were recorded. For supernormal,BMC Cancer 2006, 6:73 http://www.biomedcentral.com/1471-2407/6/73
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normal, HGPIN, and cancer compartments, grids were
presented in a random order in a Microsoft Access® data-
base for scoring. Strongly positive basal and luminal cells
were evaluated separately for all compartments except
cancer. A mean of 2,642 (range: 132–3,929) nuclei per
slide was counted for these compartments. All LGPIN
areas were evaluated. For a-casp3 and Bcl-2, only the lumi-
nal compartment was scored, as scoring basal cell cyto-
plasmic staining intensity is presumed to be too
unreliable. Both intensity of immunostaining and per-
centage of immunopositive area were recorded at 40 ×
magnification. Intensity was recorded on an ordinal scale
of 0–3, wherein 0 indicated absent staining, while 3 indi-
cated intense staining. For each 40 × field, the percent of
area positive for scores 0–3 was recorded. The sum of the
product of percent positive area and intensity gave the
final score for the 40 × field. For a-casp3 and Bcl-2, a mean
of 15 (1–33) 40 × fields was scored. Table 1 gives informa-
tion about the minimum number of nuclei/40 × fields
evaluated for each marker across the RP and CP samples.
"Near" and "far" comparison
In order to compare normal and HGPIN glands near a
focus of cancer versus those farther away, all tumor foci
were initially mapped onto the H&E slide using colored
marking pens. Different colors were used to mark out nor-
mal and HGPIN areas that were 1 mm, 5 mm and 10 mm
away from tumor. Glands that were in close proximity and
within 1 mm distance of the tumor were considered to be
"near" and glands that were at least 5 mm distance away
were considered to be "far". Glands at least 10 mm away
from tumor were preferentially evaluated whenever avail-
able. These maps were subsequently traced out on the cor-
responding immunostained slides. For Ki67 and Mcm-2,
a mean of 941 nuclei (maximum of 1264) per slide were
randomly sampled from near and far, normal and HGPIN
areas. For a-casp3 and Bcl-2, all "near" 40 × fields and at
least ten "far" 40 × fields were scored. Glands were scored
as described above.
Data analysis
Progressive compartment comparison, as well as "near"
and "far" comparison was done by computing means with
95% confidence intervals and t statistics. All statistical
analyses were performed using SAS® version 9.1(Cary,
NC). Pearson and Spearman correlation coefficients were
used to examine correlations between Ki67 and Mcm-2.
Table 1: Number of patients, cells, and 40 × microscopic fields evaluated for expression of Ki67, Mcm-2, Bcl-2, and activated caspase 3 
(a-casp3)
Tissue 
Compartment
Number of Patients Number of Cells Number of Fields
Ki67 Mcm-2 a-Casp3 Bcl-2 Ki67 Mcm-2 a-Casp3 Bcl-2
H G C a 7777 1 8 , 2 7 9 1 7 , 3 6 6 7 1 8 5
IGCa 12 12 12 11 33,302 32,735 165 195
L G C a 3333 2 , 2 1 9 3 , 1 3 0 1 0 1 5
HGPIN 12 12 13 13 23,054 27,895 188 191
LGPIN 8 8 10 10 5,300 5,561 52 44
Normal 12 12 12 12 36,141 38,542 218 224
S u p e r n o r m a l 6666 2 0 , 9 0 1 2 1 , 2 2 4 1 4 5 1 5 7
Figure 1 shows the expression of proliferation and apoptotic  markers in the various compartments of the prostate Figure 1
Figure 1 shows the expression of proliferation and apoptotic 
markers in the various compartments of the prostate. The 
immunomarkers are shown in columns from left to right 
(Ki67, Mcm-2, a-Casp3, and Bcl-2) and the compartments are 
shown in rows from top to bottom (Normal, HGPIN and 
IGCA). Normal compartment showed predominant basal cell 
(green arrows) positivity for Ki67 and Mcm-2. A shift 
towards the luminal compartment (red arrows) is noted for 
these two proliferation markers in HGPIN. Activated Cas-
pase-3 on the other hand, showed a progressive decrease in 
the luminal cell staining from normal through PIN to cancer. 
Bcl-2 did not show any differential trend across compart-
ments. Note that the strongly positive basal cells (for Bcl-2) 
serve as positive internal controls for the assay.BMC Cancer 2006, 6:73 http://www.biomedcentral.com/1471-2407/6/73
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Results
Biomarker expression across progressive tissue 
compartments
Ki67 and Mcm-2
Supernormal and normal glands showed a preponder-
ance of Ki67 and Mcm-2 positive nuclei in the basal sub-
compartment, as noted previously and as shown in Figure
1.[9,10] Mcm-2 basal cell indices were significantly higher
than Ki67 basal cell indices. The luminal, differentiated
cells of the normal and supernormal glands had lower
indices for both proliferation markers. Both Ki67 and
Mcm-2 showed an upward trend from normal tissue
through HGPIN to cancer (Fig. 2: panels A, B). Within the
cancer compartment, both Ki67 and Mcm-2 increased sig-
nificantly from low- to intermediate- to high-grade cancer.
Overall, Mcm-2 indices were higher than Ki67 indices. In
addition to the upward trend with progression in the non-
cancer areas, a shift in proliferation from the basal cell
compartment to the luminal cell compartment was noted.
There was a significant correlation between total Ki67 and
Mcm-2 indices measured in the same normal areas
(Spearman R = 0.53, p = 0.001). The Ki67: Mcm-2 corre-
A and B show percent staining for Ki67 and Mcm-2 with 95% confidence intervals across progressive tissue compartments Figure 2
A and B show percent staining for Ki67 and Mcm-2 with 95% confidence intervals across progressive tissue compartments. 
There is a strong shift in proliferation from basal to luminal cell compartments in both markers. C and D show a-casp3 and Bcl-
2 scores with 95% confidence intervals. Only the luminal compartment was scored for these 2 markers. For a-casp3 a sharp 
significant drop in expression was seen in HGPIN and cancer compartments. No differential trend was observed for Bcl-2. 
Supernormal glands showed significantly higher luminal Mcm-2 indices and higher a-casp-3 activity than normal glands sugges-
tive of a field effect.BMC Cancer 2006, 6:73 http://www.biomedcentral.com/1471-2407/6/73
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lation for the luminal and basal cell sub-compartments
were also significant (Spearman R = 0.69, p < 0.0001 and
Spearman R = 0.42, p = 0.011, respectively).
Activated caspase-3 and Bcl-2
As expected, a-casp3 demonstrated uniform and homoge-
nous cytoplasmic staining (Fig. 1) in the luminal cells of
the normal glands.[11] A significant decrease in a-casp3
expression was noted in HGPIN and cancer glands when
compared to normal glands (Fig. 2: panel C). LGPIN did
not show any significant difference in expression from
normal or supernormal glands. Within the cancer com-
partment there was no specific pattern associated with
grade. Virtually all the non-cancerous glands showed con-
sistent Bcl-2 staining in the basal cell sub-compartment.
Luminal cell staining for Bcl-2 was sparse with extremely
low numerical values on a 0–3 scale across all compart-
ments.
Evidence for field effects in prostatic carcinogenesis
Field effects by "near-far" comparison
Proliferative activity as measured by Mcm-2 expression
was significantly higher in normal glands near cancer than
ones that were more distant. This was reflected by signifi-
cantly higher luminal and total Mcm-2 indices as well as
higher luminal to basal ratios (see Table 2). However,
Ki67 did not show a significant difference between "near"
and "far" glands for the normal compartment. With
regards to apoptosis-related markers, normal "near"
glands demonstrated a higher a-casp3 activity than "far"
normal glands. No "near-far" difference for Bcl-2 expres-
sion was noted. "Near" HGPIN glands showed a high-risk
profile in terms of both proliferation and apoptotic mark-
ers. Specifically, HGPIN foci near cancer had higher Ki67
and Mcm-2 luminal and total indices, higher luminal to
basal ratios, significantly lower a-casp3, and higher Bcl-2
expression when compared to HGPIN glands that were
distant (see Table 2).
Field effects: normal versus supernormal gland comparison
Normal glands from prostates without foci of cancer had
significantly lower Mcm-2 indices when compared to nor-
mal glands from prostates containing foci of cancer (see
Fig. 2B). Also, the luminal to basal cell ratios for Ki67 and
Mcm-2 were significantly lower in the supernormal glands
(Fig. 3). Mean a-casp3 expression in the normal glands
(1.56, 95% CI: 1.45, 1.67) was significantly lower than
supernormal glands (1.84, 95% CI: 1.71, 1.98), consistent
with a field effect involving lower apoptosis in high-risk
tissue. Staining for the anti-apoptotic marker Bcl-2 in the
luminal compartment was actually higher in supernormal
compared to normal tissue (Fig. 2D). Foci of HGPIN from
cystoprostatectomy specimens did not show any differ-
ence in the biomarker expression profile compared to
HGPIN foci obtained from radical prostatectomy samples
(data not shown).
Discussion
In this study, both proliferation markers showed a pro-
gressive increase in positivity from histologically normal
prostatic glands to HGPIN to cancer. In addition, a strong
shift from basal to luminal epithelial layer proliferation
was apparent early in the progression to neoplasia. In
terms of field effects, we found that normal glands and
HGPIN glands located near foci of cancer had increased
proliferative activity, as indicated by higher Mcm-2 indi-
ces, when compared to equivalent glands that were dis-
tant. Further supporting the concept of field effects in the
prostate, we found that normal glands from prostates free
of cancer (i.e., supernormal) had lower proliferation activ-
ity when compared to normal glands from prostates that
harbored cancerous foci. The luminal to basal cell ratio for
Table 2: Ki67, Mcm-2, a-Casp3, and Bcl-2 scores in the near (<1 mm from tumor) and far (>5 mm from tumor) areas of the normal and 
HGPIN compartments. Bold numerals indicate P value < 0.05 for difference between near and far glands.
Normal HGPIN
Near mean (95% CI) Far mean (95% CI) Near mean (95% CI) Far mean (95% CI)
Ki67 (% positive)
Luminal 1.25 (0.98,1.52) 1.18 (0.88,1.48) 10.77 (10.05,11.50) 6.43 (5.48,7.38)
Basal 6.47 (5.72,7.23) 6.29 (5.41,7.16) 6.12 (4.82, 7.41) 6.85 (5.02,8.68)
Total 3.27 (2.94,3.61) 3.09 (2.71,3.47) 10.04 (9.40,10.69) 6.52 (5.68,7.37)
Lum:Basal Ratio 0.19 (0.15,0.25) 0.19 (0.14,0.25) 1.76 (1.41, 2.20) 0.94 (0.69,1.27)
Mcm-2 (%positive)
Luminal 2.17 (1.78,2.56) 1.61 (1.26,1.95) 14.75 (13.84,15.67) 7.66 (6.74,8.59)
Basal 22.45 (21.33,23.56) 22.80 (21.46,24.15) 12.91 (11.10,14.72) 16.93 (14.80,19.07)
Total 12.24 (11.62,12.86) 10.62 (9.98,11.27) 14.41 (13.59,15.23) 10.20 (9.30,11.10)
Lum:Basal Ratio 0.10 (0.08,0.12) 0.07 (0.06,0.09) 1.14 (0.98,1.33) 0.45 (0.38,0.54)
a-casp3a 1.72 (1.57,1.52) 1.52 (1.38,1.66) 0.60 (0.46,0.74) 0.88 (0.67,1.08)
Bcl-2a 0.11 (0.04,0.19) 0.13 (0.05,0.22) 0.19 (0.07,0.31) 0.05 (0.00,0.11)
a For cytoplasmic markers, the numbers in the table represent mean staining intensity in luminal cells only, scored as 0–3 per 40 × field.BMC Cancer 2006, 6:73 http://www.biomedcentral.com/1471-2407/6/73
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Ki67 and Mcm-2 was significantly lower in the supernor-
mal glands compared to the normal glands, consistent
with the hypothesis that alteration in the luminal to basal
cell proliferation ratio is an important early event in pros-
tatic carcinogenesis. In fact, luminal to basal ratio, using
either Ki67 or Mcm-2, was the strongest discriminator
between supernormal and normal glands. Our results for
the apoptosis markers were mixed. Expression of activated
caspase 3 decreased with progression and was higher in
supernormal tissue; however, in prostates containing can-
cer, a-casp3 activity appeared to be higher in normal areas
near tumor foci. The apoptosis inhibitor Bcl-2, did not
show a differential trend across pre-cancer compartments;
nor did it show expression patterns suggestive of field
effects in normal tissue. However, HGPIN areas near can-
cer foci had expression patterns indicating more inhibited
apoptosis than HGPIN areas that were distant.
HGPIN lies intermediate in the morphologic continuum
between benign and carcinomatous glands, and many
biomarkers are either upregulated or downregulated in
this neoplastic progression pathway.[12] Our observation
that Ki67 expression in HGPIN lesions was intermediate
when compared to normal and cancer, is consistent with
previous studies.[9,13-15] Higher basal Ki67 indices for
the normal compartment in our data could be due to
more detailed scoring of basal cells at higher magnifica-
tion and to the use of amplification methods to enhance
the sensitivity for detecting weak immunohistochemical
signals.
In this study, Mcm-2, a protein belonging to the Mini-
chromosome Maintenance Protein (Mcm) family, was
shown to be advantageous as a proliferation marker in
several respects. Mcm proteins, which are required for
DNA replication in all eukaryotic cells,[16] form a pre-
replicative complex by binding to specific DNA sites.
These complexes facilitate DNA replication and restrict
replication to once-per-cell cycle.[17] Mcm-2 and Ki67
were strongly correlated when comparing the same tissue
areas from the normal compartment. As noted in studies
largely performed on non-prostate tissue, the proportion
of cells positive for Mcm-2 was much higher.[9,17-19]
Meng et al. found Mcm-2 expression in non-malignant
prostate glands to be lower than we did (< 2%); however,
this difference could be due to a number of variables in
tissue preparation and analysis, including use of a differ-
ent antibody clone.[10] Transition from basal to luminal
proliferation with progression was also more evident with
Mcm-2 than with Ki67. In contrast to Ki67, which has an
undefined role in the cell cycle,[20] Mcm-2 plays a central
role in chromatin replication [21], and has a longer half-
life in replicating cells. Therefore, Mcm-2 could be more
suitable for evaluation of normal tissue with low rates of
proliferation, or in biopsy or cytology samples where tis-
sue material is relatively sparse. A low proliferative index,
such as one observes for Ki67 in normal prostate, requires
counting a large number of cells in order to achieve
acceptable statistical precision.
Another proliferation marker known to be differentially
expressed in normal, HGPIN and cancer,[22,23] is prolif-
erating nuclear cell antigen (PCNA). Antibodies against
PCNA work only on paraffin-embedded tissues, [17] and
detect cells undergoing DNA repair,[24] in addition to
proliferating cells. Mcm proteins, on the other hand, are
more specific markers for proliferation and are able to
detect proliferating cells in both frozen and paraffin tis-
sues.
Apoptotic stimuli activate initiator proteases such as cas-
pase 8 and 9; these in turn activate executioner caspases,
including caspase 3, which is the final link in the apop-
totic signal cascade.[25,26] Although our data provide
some support for activated caspase 3 as a marker of apop-
totic activity in pre-cancerous tissue, the results were not
entirely consistent because expression was actually higher
in normal areas adjacent to cancer foci. Some studies have
observed that increased apoptotic activity is linked with
increased proliferation in cancer.[27,28] This phenome-
non, which could be due to aberrant cell replication fol-
lowed by programmed cell death in more rapidly growing
tissue, could explain our results, which suggest that
decreased apoptotic activity is an indicator of high-risk
normal tissue only in the presence of low proliferative
activity. This hypothesis will require further study.
Figure 3 shows the luminal to basal cell ratio for the super- normal (normal glands from prostates without cancer) and  normal (normal glands from prostates with cancer) compart- ments Figure 3
Figure 3 shows the luminal to basal cell ratio for the super-
normal (normal glands from prostates without cancer) and 
normal (normal glands from prostates with cancer) compart-
ments. Both markers showed a significantly higher luminal: 
basal ratio in the normal compartment.BMC Cancer 2006, 6:73 http://www.biomedcentral.com/1471-2407/6/73
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Although activated or cleaved caspase 3 is an attractive
candidate marker for apoptotic activity, data on its expres-
sion in the prostate are still relatively sparse. Winter et al.,
in their study on caspase 1 and caspase 3 in the prostate,
found that caspase 3 expression was reduced in moder-
ately- and poorly-differentiated prostatic tumors com-
pared to well-differentiated carcinomas and normal
prostate.[11] Sohn et al. found that 42.5% of their cases of
benign prostatic hyperplasia met the criteria to be scored
as positive for caspase 3 versus only 28.6% of their grade
III (Gleason score 8–10) cancers.[29] Similarly, O' Neill et
al. found a significant decrease in expression of caspase 3
in high-grade cancer compared to BPH.[30] To our knowl-
edge, the present study is the first to report decreased
expression of activated caspase 3 staining in HGPIN
lesions as compared to normal glands. However,
decreased caspase 3 staining has been described in cervical
intraepithelial neoplasia when compared to normal cervi-
cal epithelium.[31]
The TUNEL assay – a widely used assay for estimation of
apoptosis – shows a progressive decrease in positive cells
from normal to HGPIN to cancer.[8] However, there are
specificity concerns with this method – areas of necrosis
or autolysis and non-apoptotic nuclei showing signs of
active gene transcription can produce false positive labe-
ling. Variation in fixation, processing techniques, and pro-
teinase digestion can also be a source of significant
error.[32-34] Direct comparison of TUNEL to activated
caspase 3 in prostate cancer xenografts has shown better
agreement for caspase 3 immunostaining with time-con-
suming morphological identification of apoptotic cells.
Our findings suggest that, while the apoptosis inhibitor
Bcl-2 might be a useful marker of HGPIN that is spatially
associated with cancer, it does not however, appear to be
a useful marker of high-risk normal tissue. Previous stud-
ies have suggested that Bcl-2 could be a promising marker
for early prostate carcinogenesis. Using a dichotomous
scoring criteria, Baltaci et al. reported Bcl-2 expression in
12 of 15 HGPIN lesions and 12 of 18 LGPIN lesions, with
staining present in both basal and luminal layers, as
opposed to basal staining only in BPH samples.[35] John-
son et al. found Bcl-2 overexpression in 34.9% cases of
HGPIN.[13] In our study, there were essentially no differ-
ences in Bcl-2 across the pre-cancer tissue compart-
ments.[13,36,37] The basal cell compartment and the
positive control sample (tonsil) displayed consistently
strong expression of Bcl-2, indicating that assay condi-
tions were optimized. This basal cell expression is consist-
ent with a prolonged lifespan and possible stem cell
function of the basal cells.[36,38] Due to the lack of vari-
ation in Bcl-2 expression in the basal layer, we scored only
the luminal layer. Since luminal expression in benign
glands was minimal or absent, there was little dynamic
range in the Bcl-2 score and, therefore, low reliability can
be expected unless much larger amounts of tissue are eval-
uated.
Field cancerization, as described by Slaughter et al. and
expanded upon by others, is the development of genetic
or epigenetic damage in normal-appearing mucosa conse-
quent to the exposure of an entire epithelial field to car-
cinogens.[3] Field effects have been implicated in the
recurrence of tumors and also in the development of sec-
ond primary tumors. Field cancerization in the prostate
could be particularly useful in characterizing molecular
signatures of apparently normal-looking mucosa adjoin-
ing a focus of cancer. Analysis of key cellular events such
as loss of heterozygosity, allelic imbalance and methyla-
tion abnormalities have been used to address the issue of
field effects at other anatomical sites.[39-41] Surprisingly,
there are very few studies on field effects in the prostate. In
the prostate, immunohistochemical evidence supporting
field effects has been shown for diverse markers including
Alpha Methylacyl-CoA Racemase (AMACR) – an enzyme
involved in branched chain fatty acid metabolism,[42,43]
EPCA – a nuclear matrix protein[44], Akt-1 – a cell sur-
vival molecule[45], and pS2 – an estrogen inducible pro-
tein.[46] Montironi et al. found lower expression of
glutathione S-transferase-π and higher expression of tel-
omerase activity in normal tissue adjoining neoplastic or
pre-neoplastic lesions.[47] Yu et al. found 1022 genes that
were differentially expressed in prostates adjacent to can-
cer when compared with organ donor prostates. Moreo-
ver, 70% of the genes were similarly altered in tumor
samples and prostates adjoining tumor, suggesting a gen-
eral similarity of expression patterns between the two.[43]
Nuclear morphometry studies in prostate have demon-
strated chromatin distribution abnormalities and subtle
changes in apparently normal-looking nuclei.[47-49]
Such alterations have been noted for a distance of 10 mm
from the margin of a either a PIN or an adenocarcinoma
focus.[49]. Montironi.et al. reported that PIN lesions from
cystoprostatectomy specimens had significantly lower
mean nuclear and nucleolar area when compared to sim-
ilar lesions from radical prostatectomy specimens. This
study also found, in agreement with our results, that Ki67
indices in PIN lesions from cystoprostatectomy and radi-
cal prostatectomy specimens were not meaningfully dif-
ferent.[50].
Proliferation markers have been used to study field can-
cerization at other sites. In their study on hamster cheek
pouch carcinogenesis model, Raimondi et al. found that
ploidy values and 5-bromo-2-deoxiuridine (BrdU) were
higher in carcinogen-exposed epithelia with no unusual
microscopic features when compared to control epithe-
lia.[51] Similarly, Barsky et al. found that Ki67 indices in
normal bronchial mucosa of smokers were higher thanBMC Cancer 2006, 6:73 http://www.biomedcentral.com/1471-2407/6/73
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that of non-smokers.[52] We are not aware of previous
reports on the use of caspase 3 or any other apoptotic
marker for the evaluation of field effects.
In summary, we demonstrate that biomarkers identifying
key cellular events like proliferation and apoptosis are
altered not only in preneoplastic lesions but also in appar-
ently normal-looking epithelium. Data obtained from
normal tissues adjoining a prostate cancer focus need to
be interpreted in the light of the fact that these tissues are
subject to field effects. We conclude that Mcm-2 could be
superior to Ki67 for detection of subtle field effects, and
that activated caspase-3 shows some promise as an indica-
tor of high-risk normal tissue. The implication, however,
that normal areas immediately adjacent to cancer might
have increases in both proliferation and apoptosis com-
pared to distant areas suggests that the balance between
these two processes rather than their absolute levels could
be important or, to state it differently, the significance of
the level of apoptosis in an area depends on the level of
proliferation, and vice-versa. Future plans call for imple-
mentation of a multivariate model comprised of various
biomarkers and clinical variables to predict outcomes fol-
lowing negative biopsies in a larger study set.
Abbreviations
A-casp3, activated caspase-3; Bcl-2, B-Cell Leukemia/Lym-
phoma-2; BPH, benign prostatic hyperplasia; CP, cysto-
prostatectomy; DAB, Diaminobenzidine; H&E
hematoxylin and eosin; HGCA, high-grade cancer;
HGPIN, high grade prostatic intraepithelial neoplasia;
IGCA, intermediate-grade cancer; LGCA, low-grade can-
cer; LGPIN, low grade prostatic intraepithelial neoplasia;
Mcm-2, Minichromosome Maintenance Protein-2; RP,
radical prostatectomy
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
VA read out the H&E slides, scored the immunostained
slides and drafted the manuscript. RJD carried out the data
analysis. XYJ and MRP were involved in expert classifica-
tion of the various histopathological lesions. PHG con-
ceived the study, participated in its design and
coordination and helped to draft the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by research grants P50 CA 90386 and R01 CA 
90759 from the National Institutes of Health and the National Cancer Insti-
tute. The authors gratefully acknowledge Bella Shmaltsuyev, Misop Han, 
Girish Venkataraman, and Rick Lowe for their assistance on this project.
References
1. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH: A
genetic explanation of Slaughter's concept of field canceriza-
tion: evidence and clinical implications.  Cancer Res 2003,
63:1727-1730.
2. Braakhuis BJ, Leemans CR, Brakenhoff RH: Expanding fields of
genetically altered cells in head and neck squamous carcino-
genesis.  Semin Cancer Biol 2005, 15:113-120.
3. Slaughter DP, Southwick HW, Smejkal W: Field cancerization in
oral stratified squamous epithelium; clinical implications of
multicentric origin.  Cancer 1953, 6:963-968.
4. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy
T, Ritchey DM, Miller YE: Widely dispersed p53 mutation in res-
piratory epithelium. A novel mechanism for field carcino-
genesis.  J Clin Invest 1997, 100:2133-2137.
5. Copper MP, Braakhuis BJ, de Vries N, van Dongen GA, Nauta JJ, Snow
GB: A panel of biomarkers of carcinogenesis of the upper
aerodigestive tract as potential intermediate endpoints in
chemoprevention trials.  Cancer 1993, 71:825-830.
6. Porter CR, Crawford ED: Combining artificial neural networks
and transrectal ultrasound in the diagnosis of prostate can-
cer.  Oncology 2003, 17:1395-9, 1403-6.
7. Epstein JI, Grignon DJ, Humphrey PA, McNeal JE, Sesterhenn IA,
Troncoso P, Wheeler TM: Interobserver reproducibility in the
diagnosis of prostatic intraepithelial neoplasia.  Am J Surg Pathol
1995, 19:873-886.
8. Zeng L, Kyprianou N: Apoptotic regulators in prostatic intraep-
ithelial neoplasia (PIN): value in prostate cancer detection
and prevention.  Prostate Cancer Prostatic Dis 2005, 8:7-13.
9. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG: DNA
replication regulation protein Mcm7 as a marker of prolifer-
ation in prostate cancer.  J Clin Pathol 2004, 57:1057-1062.
10. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley
TW, Weinberg V, Carroll PR, Tlsty TD: Minichromosome main-
tenance protein 2 expression in prostate: characterization
and association with outcome after therapy for cancer.  Clin
Cancer Res 2001, 7:2712-2718.
11. Winter RN, Kramer A, Borkowski A, Kyprianou N: Loss of cas-
pase-1 and caspase-3 protein expression in human prostate
cancer.  Cancer Res 2001, 61:1227-1232.
12. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J,
Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B: Human
prostate cancer risk factors.  Cancer 2004, 101:2371-2490.
13. Johnson MI, Robinson MC, Marsh C, Robson CN, Neal DE, Hamdy
FC: Expression of Bcl-2, Bax, and p53 in high-grade prostatic
intraepithelial neoplasia and localized prostate cancer: rela-
tionship with apoptosis and proliferation.  Prostate 1998,
37:223-229.
14. Mucci NR, Rubin MA, Strawderman MS, Montie JE, Smith DC, Pienta
KJ: Expression of nuclear antigen Ki-67 in prostate cancer
needle biopsy and radical prostatectomy specimens.  J Natl
Cancer Inst 2000, 92:1941-1942.
15. Tamboli P, Amin MB, Schultz DS, Linden MD, Kubus J: Comparative
analysis of the nuclear proliferative index (Ki-67) in benign
prostate, prostatic intraepithelial neoplasia, and prostatic
carcinoma.  Mod Pathol 1996, 9:1015-1019.
16. Dutta A, Bell SP: Initiation of DNA replication in eukaryotic
cells.  Annu Rev Cell Dev Biol 1997, 13:293-332.
17. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH,
Coleman N: Minichromosome maintenance proteins as bio-
logical markers of dysplasia and malignancy.  Clin Cancer Res
1999, 5:2121-2132.
18. Chatrath P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K,
Vowler SL, Grant JW, Saeed IT, Howard D, Laskey RA, Coleman N:
Aberrant expression of minichromosome maintenance pro-
tein-2 and Ki67 in laryngeal squamous epithelial lesions.  Br J
Cancer 2003, 89:1048-1054.
19. Rodins K, Cheale M, Coleman N, Fox SB: Minichromosome main-
tenance protein 2 expression in normal kidney and renal cell
carcinomas: relationship to tumor dormancy and potential
clinical utility.  Clin Cancer Res 2002, 8:1075-1081.
20. Brown DC, Gatter KC: Ki67 protein: the immaculate decep-
tion?  Histopathology 2002, 40:2-11.
21. Takisawa H, Mimura S, Kubota Y: Eukaryotic DNA replication:
from pre-replication complex to initiation complex.  Curr Opin
Cell Biol 2000, 12:690-696.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2006, 6:73 http://www.biomedcentral.com/1471-2407/6/73
Page 9 of 9
(page number not for citation purposes)
22. Myers RB, Grizzle WE: Biomarker expression in prostatic
intraepithelial neoplasia.  Eur Urol 1996, 30:153-166.
23. Montironi R, Magi Galluzzi CM, Marina S, Diamanti L: Quantitative
characterization of the frequency and location of cell prolif-
eration and death in prostate pathology.  J Cell Biochem Suppl
1994, 19:238-245.
24. Xue WC, Khoo US, Ngan HY, Chan KY, Chiu PM, Tsao SW, Cheung
AN: Minichromosome maintenance protein 7 expression in
gestational trophoblastic disease: correlation with Ki67,
PCNA and clinicopathological parameters.  Histopathology
2003, 43:485-490.
25. Wolf BB, Schuler M, Echeverri F, Green DR: Caspase-3 is the pri-
mary activator of apoptotic DNA fragmentation via DNA
fragmentation factor-45/inhibitor of caspase-activated
DNase inactivation.  J Biol Chem 1999, 274:30651-30656.
26. Kumar V, Cotran RS, Robbins SL: Robbins basic pathology.  7th
edition. Philadelphia, Saunders; 2003:xii, 873. 
27. Yamasaki F, Tokunaga O, Sugimori H: Apoptotic index in ovarian
carcinoma: correlation with clinicopathologic factors and
prognosis.  Gynecol Oncol 1997, 66:439-448.
28. Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S,
Sabattini E, Gherlinzoni F, Tosi P, Kraft R, et al.:  Correlations
between apoptotic and proliferative indices in malignant
non-Hodgkin's lymphomas.  Am J Pathol 1993, 142:755-763.
29. Sohn JH, Kim DH, Choi NG, Park YE, Ro JY: Caspase-3/CPP32
immunoreactivity and its correlation with frequency of
apoptotic bodies in human prostatic carcinomas and benign
nodular hyperplasias.  Histopathology 2000, 37:555-560.
30. O'Neill AJ, Boran SA, O'Keane C, Coffey RN, Hegarty NJ, Hegarty P,
Gaffney EF, Fitzpatrick JM, Watson RW: Caspase 3 expression in
benign prostatic hyperplasia and prostate carcinoma.  Pros-
tate 2001, 47:183-188.
31. Zanotti S, Fisseler-Eckhoff A, Mannherz HG: Changes in the topo-
logical expression of markers of differentiation and apopto-
sis in defined stages of human cervical dysplasia and
carcinoma.  Gynecol Oncol 2003, 89:376-384.
32. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS,
Blomme EA: Comparison of immunohistochemistry for acti-
vated caspase-3 and cleaved cytokeratin 18 with the TUNEL
method for quantification of apoptosis in histological sec-
tions of PC-3 subcutaneous xenografts.  J Pathol 2003,
199:221-228.
33. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bur-
sch W, Schulte-Hermann R: In situ detection of fragmented
DNA (TUNEL assay) fails to discriminate among apoptosis,
necrosis, and autolytic cell death: a cautionary note.  Hepatol-
ogy 1995, 21:1465-1468.
34. Kockx MM, Muhring J, Knaapen MW, de Meyer GR: RNA synthesis
and splicing interferes with DNA in situ end labeling tech-
niques used to detect apoptosis.  Am J Pathol 1998, 152:885-888.
35. Baltaci S, Orhan D, Ozer G, Tolunay O, Gogous O: Bcl-2 proto-
oncogene expression in low- and high-grade prostatic
intraepithelial neoplasia.  BJU Int 2000, 85:155-159.
36. Catz SD, Johnson JL: BCL-2 in prostate cancer: a minireview.
Apoptosis 2003, 8:29-37.
37. Haussler O, Epstein JI, Amin MB, Heitz PU, Hailemariam S: Cell pro-
liferation, apoptosis, oncogene, and tumor suppressor gene
status in adenosis with comparison to benign prostatic
hyperplasia, prostatic intraepithelial neoplasia, and cancer.
Hum Pathol 1999, 30:1077-1086.
38. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M,
Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-
suppressing oncoprotein bc1-2 in hormone-refractory
human prostate cancers.  Am J Pathol 1993, 143:390-400.
39. Tabor MP, Brakenhoff RH, van Houten VM, Kummer JA, Snel MH,
Snijders PJ, Snow GB, Leemans CR, Braakhuis BJ: Persistence of
genetically altered fields in head and neck cancer patients:
biological and clinical implications.  Clin Cancer Res 2001,
7:1523-1532.
40. Ellsworth DL, Ellsworth RE, Love B, Deyarmin B, Lubert SM, Mittal V,
Hooke JA, Shriver CD: Outer breast quadrants demonstrate
increased levels of genomic instability.  Ann Surg Oncol 2004,
11:861-868.
41. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J,
Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts
DS, Hamilton SR, Issa JP: MGMT promoter methylation and
field defect in sporadic colorectal cancer.  J Natl Cancer Inst
2005, 97:1330-1338.
42. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH: Alpha-
methylacyl-CoA racemase (AMACR) expression in normal
prostatic glands and high-grade prostatic intraepithelial neo-
plasia (HGPIN): Association with diagnosis of prostate can-
cer.  Prostate 2004.
43. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Tho-
mas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH:
Gene expression alterations in prostate cancer predicting
tumor aggression and preceding development of malig-
nancy.  J Clin Oncol 2004, 22:2790-2799.
44. Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Master-
son R, Getzenberg RH: Early identification of individuals with
prostate cancer in negative biopsies.  J Urol 2004,
171:1419-1423.
45. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M,
Wheeler T, Harper W: High levels of phosphorylated form of
Akt-1 in prostate cancer and non-neoplastic prostate tissues
are strong predictors of biochemical recurrence.  Clin Cancer
Res 2004, 10:6572-6578.
46. Bonkhoff H, Stein U, Welter C, Remberger K: Differential expres-
sion of the pS2 protein in the human prostate and prostate
cancer: association with premalignant changes and neuroen-
docrine differentiation.  Hum Pathol 1995, 26:824-828.
47. Montironi R, Hamilton PW, Scarpelli M, Thompson D, Bartels PH:
Subtle morphological and molecular changes in normal-
looking epithelium in prostates with prostatic intraepithelial
neoplasia or cancer.  Eur Urol 1999, 35:468-473.
48. Mairinger T, Mikuz G, Gschwendtner A: Nuclear chromatin tex-
ture analysis of nonmalignant tissue can detect adjacent pro-
static adenocarcinoma.  Prostate 1999, 41:12-19.
49. Bartels PH, Montironi R, Hamilton PW, Thompson D, Vaught L, Bar-
tels HG: Nuclear chromatin texture in prostatic lesions. II.
PIN and malignancy associated changes.  Anal Quant Cytol Histol
1998, 20:397-406.
50. Montironi R, Mazzucchelli R, Santinelli A, Scarpelli M, Beltran AL,
Bostwick DG: Incidentally detected prostate cancer in cysto-
prostatectomies: pathological and morphometric compari-
son with clinically detected cancer in totally embedded
specimens.  Hum Pathol 2005, 36:646-654.
51. Raimondi A, Cabrini R, Itoiz ME: Ploidy analysis of field canceri-
zation and cancer development in the hamster cheek pouch
carcinogenesis model.  J Oral Pathol Med 2005, 34:227-231.
52. Barsky SH, Roth MD, Kleerup EC, Simmons M, Tashkin DP: His-
topathologic and molecular alterations in bronchial epithe-
lium in habitual smokers of marijuana, cocaine, and/or
tobacco.  J Natl Cancer Inst 1998, 90:1198-1205.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/73/prepub